B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2236-2243

  Della Torre, Emanuel ^a,b   Feeney, Eoin ^c   Deshpande, Vikram ^c   Mattoo, Hamid ^a   Mahajan, Vinay ^a   Kulikova, Maria ^a   Wallace, Zachary S ^c   Carruthers, Mollie ^c   Chung, Raymond T ^c   Pillai, Shiv ^a   Stone, John H ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CD20 ANTIGEN; CD3 ANTIGEN; HYALURONIC ACID; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; RITUXIMAB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; IMMUNOGLOBULIN G;

ARTICLE; CELL ACTIVATION; CELL POPULATION; CLINICAL ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENHANCED LIVER FIBROSIS SCORE; ERYTHROCYTE SEDIMENTATION RATE; FIBROSIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; LYMPHOCYTIC INFILTRATION; MORPHOMETRICS; MYOFIBROBLAST; PHENOTYPE; PLASMABLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RETROPERITONEUM; SCORING SYSTEM; SKIN BIOPSY; ADULT; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOPSY; BLOOD; CELLULAR IMMUNITY; DISEASE COURSE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BIOPSY; DISEASE PROGRESSION; FEMALE; FIBROSIS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOFIBROBLASTS;

EID: 84954311741     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205799     Document Type: Article

References (35)

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539-51.
2. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-92.
3. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061-7.
4. Yamamoto M, Takahashi H, Ohara M, et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006;16:335-40.
5. Geyer JT, Ferry JA, Harris NL, et al. Chronic sclerosing sialadenitis (Küttner tumor) is an IgG4-associated disease. Am J Surg Pathol 2010;34:202-10.
6. Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010;62:1312-18.
7. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006;41:613-25.
8. Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: 'idiopathic' retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 2013;92:82-91.
9. Della Torre E, Bozzolo EP, Passerini G, et al. IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. Ann Intern Med 2012;156:401-3.
10. Mahajan VS, Mattoo H, Deshpande V, et al. IgG4-related disease. Annu Rev Pathol 2014;9:315-47.
11. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012;91:57-66.
12. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62:1755-62.
13. Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015;74:190-5.
14. Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014. doi: 10.1016/j.jaci.2014.03.034
15. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011;23:67-71.
16. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-51.
17. Abignano G, Cuomo G, Buch MH, et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis 2014;73:420-7.
18. Carruthers MN, Stone JH, Deshpande V, et al. Development of an IgG4-RD responder index. Int J Rheumatol 2012;2012:259408.
19. Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236-42.
20. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011;18:23-31.
21. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015;74:1188-94.
22. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9.
23. Geri G, Terrier B, Imbert-Bismut F, et al. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab. J Viral Hepat 2012;19:497-500.
24. François A, Chatelus E, Wachsmann D, et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013;15:R168.
25. Lighaam LC, Aalberse RC, Rispens T. IgG4-Related fibrotic diseases from an immunological perspective: regulators out of control? Int J Rheumatol 2012;2012:789164.
26. Yang M, Rui K, Wang S, et al. Regulatory B cells in autoimmune diseases. Cell Mol Immunol 2013;10:122-32.
27. Sato S, Hayakawa I, Hasegawa M, et al. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003;120:542-7.
28. Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system. J Immunol 2014;192:929-39.
29. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
30. Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol 2013;31:107-35.
31. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
32. Hinz B, Celetta G, Tomasek JJ, et al. α-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 2001;12:2730-41.
33. Jiang F, Parsons CJ, Stefanovic B. Gene-expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 2006;45:401-9.
34. Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012;109:9448-53.
35. Pratt WB. The mechanism of glucocorticoid effects in fibroblasts. J Invest Dermatol 1978;71:24-35.